Nexalin Awarded Key Patent for Deep Brain Stimulation Device

New York, January 29, 2024 - PRISM MarketView - Nexalin Technology (Nasdaq: NXL) has been awarded a key patent relating to the company’s non-invasive, frequency-based deep brain stimulation device by the United States Patent and Trademark Office (USPTO).

Mark White, CEO of Nexalin Technology said the patent award marks a major milestone for Nexalin, extending its IP protection through 2040.

“At Nexalin, we are highly encouraged that our DIFS® technique will improve mental healthcare outcomes among patients.  Specifically, clinical studies have demonstrated therapeutic benefits in conditions ranging from treatment-resistant depression to migraines, anxiety, and insomnia. We are also targeting mental health conditions such as addiction, substance use disorder, Alzheimer’s, traumatic brain injury (TBI) and PTSD.”

The newly-issued patent covers the core technology utilized in the Company’s Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner.

Nexalin believes its neurostimulation device has the potential to transform the standard of care for the treatment of mental health disorders. The company is focused on advancing the commercial rollout, including expanding its regulatory approvals in overseas markets, as well as pursuing regulatory clearance in the U.S.

The global mental health market was an estimated $383 billion in 2020 and is projected to reach $537 billion by 2030.

Nexalin designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp (mA) neurostimulation device was recently approved in China by the National Medical Products Administration (NMPA) for the treatment of insomnia and depression. Additional information about the Company is available at: https://nexalin.com/.

Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Website: https://prismmarketview.com